North Star Asset Management Inc. Invests $1.22 Million in IQVIA Holdings Inc. $IQV

North Star Asset Management Inc. acquired a new stake in IQVIA Holdings Inc. (NYSE:IQV) during the 2nd quarter, according to its most recent disclosure with the SEC. The fund acquired 6,320 shares of the medical research company’s stock, valued at approximately $1,221,000.

Other institutional investors also recently modified their holdings of the company. Financial Freedom LLC bought a new stake in IQVIA in the 1st quarter valued at approximately $25,000. Ascentis Independent Advisors bought a new position in shares of IQVIA during the 1st quarter worth approximately $25,000. International Assets Investment Management LLC acquired a new stake in shares of IQVIA in the fourth quarter valued at approximately $27,000. Compass Financial Management LLC bought a new stake in shares of IQVIA in the second quarter worth $27,000. Finally, Gilpin Wealth Management LLC bought a new stake in shares of IQVIA in the fourth quarter worth $27,000. 89.62% of the stock is currently owned by institutional investors.

Insider Transactions at IQVIA

In other news, insider Keriann Cherofsky sold 558 shares of IQVIA stock in a transaction on Wednesday, July 29th. The stock was sold at an average price of $245.21, for a total transaction of $136,827.18. Following the completion of the sale, the insider owned 2,989 shares of the company’s stock, valued at approximately $732,932.69. This trade represents a 15.73% decrease in their ownership of the stock. The transaction was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through this hyperlink. Also, insider Eric Sherbet sold 5,000 shares of the business’s stock in a transaction dated Wednesday, July 29th. The shares were sold at an average price of $249.16, for a total transaction of $1,245,800.00. Following the completion of the sale, the insider directly owned 20,999 shares of the company’s stock, valued at approximately $5,232,110.84. The trade was a 19.23% decrease in their position. The SEC filing for this sale provides additional information. In the last 90 days, insiders sold 12,913 shares of company stock valued at $3,098,793. 1.70% of the stock is currently owned by company insiders.

Analysts Set New Price Targets

Several brokerages have issued reports on IQV. TD Cowen lifted their price target on shares of IQVIA from $233.00 to $288.00 and gave the company a “buy” rating in a research note on Wednesday, July 29th. Wall Street Zen lowered IQVIA from a “buy” rating to a “hold” rating in a report on Saturday. Stifel Nicolaus boosted their price target on IQVIA from $220.00 to $276.00 and gave the stock a “buy” rating in a research report on Wednesday, July 29th. Royal Bank Of Canada upped their price objective on IQVIA from $221.00 to $247.00 and gave the stock an “outperform” rating in a research note on Wednesday, July 29th. Finally, JPMorgan Chase & Co. raised their target price on shares of IQVIA from $225.00 to $285.00 and gave the company an “overweight” rating in a research note on Wednesday, July 29th. One equities research analyst has rated the stock with a Strong Buy rating, thirteen have issued a Buy rating and three have given a Hold rating to the company’s stock. According to MarketBeat, the company presently has a consensus rating of “Moderate Buy” and a consensus price target of $241.88.

IQVIA Stock Performance

NYSE IQV opened at $260.48 on Friday. IQVIA Holdings Inc. has a 52-week low of $154.50 and a 52-week high of $265.25. The stock has a market cap of $42.88 billion, a PE ratio of 32.32, a P/E/G ratio of 2.24 and a beta of 1.18. The firm has a 50-day moving average of $222.14 and a 200-day moving average of $189.62. The company has a debt-to-equity ratio of 2.18, a quick ratio of 0.71 and a current ratio of 0.71.

IQVIA (NYSE:IQV) last released its quarterly earnings results on Tuesday, July 28th. The medical research company reported $3.15 earnings per share for the quarter, beating the consensus estimate of $3.03 by $0.12. IQVIA had a net margin of 8.10% and a return on equity of 30.25%. The firm had revenue of $4.37 billion for the quarter, compared to analysts’ expectations of $4.30 billion. During the same period in the prior year, the firm earned $2.81 EPS. The business’s revenue was up 8.7% on a year-over-year basis. IQVIA has set its FY 2026 guidance at 12.800-13.000 EPS. On average, sell-side analysts anticipate that IQVIA Holdings Inc. will post 11.57 EPS for the current year.

IQVIA declared that its Board of Directors has initiated a share buyback program on Thursday, May 7th that allows the company to buyback $2.00 billion in outstanding shares. This buyback authorization allows the medical research company to buy up to 6.8% of its stock through open market purchases. Stock buyback programs are often an indication that the company’s leadership believes its stock is undervalued.

IQVIA Company Profile

IQVIA (NYSE: IQV) is a global provider of advanced analytics, technology solutions and contract research services to the life sciences industry. The company combines clinical research capabilities with large-scale health data and analytics to support drug development, regulatory reporting, commercial strategy and real‑world evidence generation. IQVIA traces its current form to the combination of Quintiles and IMS Health announced in 2016 and subsequently rebranded as IQVIA, bringing together long-established clinical research operations and extensive healthcare information assets.

IQVIA’s principal activities include outsourced clinical development services (acting as a contract research organization for phases I–IV), real‑world evidence and observational research, regulatory and safety services, and a suite of technology platforms that enable data integration, analytics and operational management.